Related Experiment Video
Updated: Oct 31, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
798
Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer
María Berdasco1,2, Manel Esteller3,4,5,6
1Epigenetic Therapies Group, Experimental and Clinical Hematology Program (PHEC), Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
British Journal of Pharmacology
|June 29, 2021
Summary
Epitranscriptomics studies RNA modifications, revealing their role in cancer. This review explores targeting these RNA marks with drugs for cancer treatment, highlighting current challenges and future potential.
Area of Science:
- Biochemistry and Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Epitranscriptomics investigates biochemical modifications of RNA, providing insights into cellular processes.
- Recent advancements enable characterization and quantification of RNA modifications.
- Aberrant epitranscriptomes are increasingly linked to human diseases, particularly cancer.
Purpose of the Study:
- To review key RNA modifications, focusing on mRNA.
- To summarize evidence of RNA modification dysregulation in cancer.
- To provide an overview of drug discovery efforts targeting the epitranscriptome.
Main Methods:
- Literature review of epitranscriptomic research.
- Analysis of scientific evidence linking RNA modifications to cancer.
- Survey of current drug discovery strategies for epitranscriptomic targets.
Main Results:
- Detailed description of principal RNA modifications, especially on mRNA.
- Compilation of data showing RNA modification alterations in various cancers.
- Overview of the current landscape of small molecule compounds targeting the epitranscriptome.
Conclusions:
- Epitranscriptomics presents potential therapeutic targets for cancer.
- Targeting RNA modifications with low molecular weight compounds is a promising, yet challenging, area.
- Further advancements in chemical biology and drug development are crucial for clinical translation.
Related Concept Videos
01:22MicroRNAs
3.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
01:22MicroRNAs
22.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.6K
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:23RNA Interference
26.9K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.9K
02:23RNA Editing
9.3K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.3K
02:15Experimental RNAi
6.6K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.6K